Sertraline and Naltrexone for Alcohol Dependence - Full Text View

Sertraline and Naltrexone for Alcohol Dependence

This study has been completed.

Sponsored by:	National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Information provided by:	National Institute on Alcohol Abuse and Alcoholism (NIAAA)
ClinicalTrials.gov Identifier:	NCT00000440

Purpose

This study is a double-blind, placebo-controlled outpatient trial to improve, through the addition of sertraline (Zoloft), the abstinence and relapse rates in alcohol- dependent individuals currently taking naltrexone (Revia).

Condition	Intervention	Phase
Alcoholism	Drug: naltrexone (Revia) Drug: sertraline (Zoloft)	Phase II

MedlinePlus related topics:

Alcoholism

ChemIDplus related topics:

Sertraline hydrochloride Sertraline Naltrexone Naltrexone hydrochloride Ethanol

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Efficacy Study

Official Title:	Sertraline and Naltrexone for Alcohol Dependents

Further study details as provided by National Institute on Alcohol Abuse and Alcoholism (NIAAA):

Estimated Enrollment:	124
Estimated Study Completion Date:	September 2002

Eligibility

Ages Eligible for Study:	18 Years to 55 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Meets the criteria for alcohol dependence.
Abstinent from alcohol for a period of at least 5 days and not greater than 30 days.
Able to read English and complete study evaluations.
A stable residence and a telephone to ensure that subjects can be located during the study.

Exclusion Criteria:

Currently meets criteria for substance abuse or dependence with the exception of nicotine dependence.
Current use of disulfiram (Antabuse) or a MAO Inhibitor.
Psychotic or otherwise severely psychiatrically disabled (i.e., depressed, suicidal, current mania).
Major depression at the time of assessment.
Previous treatment with naltrexone (Revia) for alcohol dependence.
Significant underlying medical conditions such as cerebral, renal, thyroid, or cardiac disease.
Abstinent longer than 30 days prior to admission to program.
Hepatocellular disease or elevated bilirubin levels.
Females who are pregnant, nursing, or not using a reliable method of birth control.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000440

Locations


United States, New York
	Department of Psychiatry, Mount Sinai School of Medicine
	New York, New York, United States, 10029

Sponsors and Collaborators

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

More Information

Study ID Numbers:	NIAAAFAR11222
First Received:	November 2, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000440
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Mental Disorders

Naltrexone

Alcoholism

Substance-Related Disorders

Sertraline

Disorders of Environmental Origin

Alcohol-Related Disorders

Serotonin

Ethanol

Additional relevant MeSH terms:

Neurotransmitter Uptake Inhibitors

Neurotransmitter Agents

Molecular Mechanisms of Pharmacological Action

Narcotic Antagonists

Physiological Effects of Drugs

Psychotropic Drugs

Serotonin Uptake Inhibitors

Pharmacologic Actions

Serotonin Agents

Sensory System Agents

Therapeutic Uses

Peripheral Nervous System Agents

Central Nervous System Agents

Antidepressive Agents

ClinicalTrials.gov processed this record on September 05, 2008